8th Annual

Protein-Protein Interactions

Targeting PPIs for Therapeutic Interventions

April 21-22, 2015 


The Drug Discovery Chemistry conference offers a compact, dynamic event over
three days that allows the scientific community an excellent opportunity to stay aware of current trends.

Kenneth D., Director, FLAMMA

Many biologically important processes are regulated by protein complexes. Such protein-protein interactions (PPIs) or protein-DNA interactions were considered ‘undruggable’ until recently. Because PPIs have no enzymatic activity to inhibit, using traditional biochemical-based high-throughput assays to screen for inhibitors against PPIs has not been an option. However new screening technologies, such as those based on coupling energy transfer between interacting proteins to a screening-amenable read-out, have enabled progress. But the main driver of recent PPI successes has been biophysical techniques such as surface plasma resonance (SPR) and nuclear magnetic resonance (NMR), sometimes using fragment-based approaches, that have resulted in inhibitors against even difficult PPIs. Computational approaches based on crystal structures of the PPIs being targeted have also accelerated drug design against PPIs.

Challenges still exist though in PPI-targeted drug design: should we inhibit the PPI directly or allosterically? Which interface should be targeted and how much of it? How stongly does the inhibitor need to bind? Cambridge Healthtech Institute once again convenes leading scientists in the field to share their knowledge with peers at Protein-Protein Interactions, a day-and-a-half meeting that is in the first half of CHI's larger Drug Discovery Chemistry event.

Topics may include, but are not limited to: 

  • Novel assay (biochemical and functional/cell-based) technologies to detect/screen for PPIs
  • Fragment-based campaigns for initial hit finding
  • Structure-based drug design to optimize lead candidates
  • Discovery and optimization challenges unique to PPI drug development
  • Macrocyclics against PPIs
  • Case studies on PPI-targeted compounds progressing in drug development in areas such as cancer and inflammation
  • New PPI targets in intracellular signal transduction, transcription, immunomodulation, anti-virals, epigenetics and protein homeostasis (ubiquitination and protein misfolding)

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is September 29, 2014 

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program.  Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships. 

For more details on the conference, please contact: 
Anjani Shah, Ph.D.
Conference Director
Cambridge Healthtech Institute
Phone: (914) 723-0255
Email: ashah@healthtech.com 

For partnering and sponsorship information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412
Email: cbenton@healthtech.com